-- Dr. Robert F. Cathcart, M.D. ---
--- Allergy, Environmental, and ---
----- Orthomolecular Medicine ----- 
------- Orthopedic Medicine -------
--- 127 Second Street,  Suite 4 ---
--- Los Altos,  California, USA ---
---- Telephone:   650-949-2822 ----
---- Fax:         650-949-5083 ----
Copyright (C), 1994 and prior years, Dr. Robert F. Cathcart.
Permission granted to distribute via  the internet  as long 
as material is distributed in its entirity and not modified.

Medical Hypotheses, 18:61-77, 1985.



(C) Robert F. Cathcart, III Allergy, Environmental, and Orthomolecular Medicine 127 Second Street, Los Altos, California 94022, USA Telephone 650-949-2822


The amount of oral ascorbic acid that a patient can tolerate without diarrhea, increases somewhat proportionately to the "toxicity" of his disease. Clinically, in a disease ameliorated by ascorbate, there is a suppression of symptoms only with very high doses and approximately to that extent which a nonrate-limited,_antioxidant_free_radical_scavenger, might be expected to affect that disease process if all harmful free radicals and highly reactive oxidizing substances were quenched. In most pathologic processes, the rate at which free radicals and highly reactive oxidants are produced, exceeds the rate at which the ordinary rate-limited antioxidant free radical scavenging mechanisms can quench those free radicals and oxidants. When ascorbate acts as a scavenger, dehydroascorbate is formed; but if the ascorbate/dehydroascorbate (AA/DHA) ratio is kept high (the redox potential kept reducing) until the unstable dehydro- ascorbate undergoes hydrolysis or can be reduced back to ascorbate, the dehydroascorbate will do no harm. Since even at very high doses, ascorbate is virtually nontoxic, it may be given in the enormous doses necessary to quench almost all unwanted free radicals and oxidants. The wide spectrum of infectious diseases ameliorated by massive doses of ascorbate indicates some common pathologic processes in these diseases.


Based on my experience with over 11,000 patients during the past 14 years, it has been my consistent observation that the amount of ascorbic acid dissolved in water which a patient, tolerant to ascorbic acid, can ingest orally without producing diarrhea, increases considerably somewhat proportionately with the "toxicity" of his illness. A person who can tolerate orally 10 to 15 grams of ascorbic acid per 24 hours when well, might be able to tolerate 30 to 60 grams per 24 hours if he has a mild cold, 100 grams with a severe cold, 150 grams with influenza, and 200 grams per 24 hours with mononucleosis or viral pneumonia. The clinical symptoms of these diseases and other conditions previously described, are markedly ameliorated only as bowel_tolerance dose levels (the amount that almost, but not quite, causes diarrhea) are approached (1-6).


                                   GRAMS PER         NUMBER OF DOSES 

CONDITION                          24 HOURS          PER 24 HOURS
      normal                       4 -  15              4 -  6 
      mild cold                   30 -  60              6 - 10 
      severe cold                 60 - 100+             8 - 15 
      influenza                  100 - 150              8 - 20 
      ECHO, coxsackievirus       100 - 150              8 - 20 
      mononucleosis              150 - 200+            12 - 25 
      viral pneumonia            100 - 200+            12 - 25 
      hay fever, asthma           15 -  50              4 -  8 
      environmental and 
       food allergy              0.5 -  50              4 -  8 
      burn, injury, surgery       25 - 150+             6 - 20 
      anxiety, exercise and 
       other mild stresses        15 -  25              4 -  6 
      cancer                      15 - 100              4 - 15 
      ankylosing spondylitis      15 - 100              4 - 15 
      Reiter's syndrome           15 -  60              4 - 10 
      acute anterior uveitis      30 - 100              4 - 15 
      rheumatoid arthritis        15 - 100              4 - 15 
      bacterial infections        30 - 200+            10 - 25 
      infectious hepatitis        30 - 100              6 - 15 
      candidiasis                 15 - 200+             6 - 25 

There was a remarkable lack of systemic difficulties in these patients that could be directly related to the massive doses of ascorbate. The majority of these patients, ill with some acute or chronic disease, were able to take massive doses of ascorbic acid orally without difficulties. Minor complaints about ascorbic acid such as it causing gas, diarrhea, or acid stomach, while common in well persons even at low doses, were rare in very sick patients. Low or moderate doses (doses substantially below bowel tolerance) usually had no noticeable immediate beneficial effects, but high doses (doses just below the amount that would produce diarrhea in a patient tolerant to ascorbate) would have the effect of markedly suppressing symptoms as the high dose levels were reached. This sudden effect is often quite dramatic clinically and is not usually obtained even partially at lower doses. It is as if a threshold were reached at which point the ascorbate becomes very effective.

Mixtures of mineral ascorbates (calcium, magnesium, potassium, zinc, and sometimes sodium) are used in certain circumstances to increase bowel tolerance for even more clinical effectiveness but do not clearly demonstrate the increasing bowel tolerance phenomenon being discussed here.

Knowledge of the known vitamin functions of ascorbate would not have allowed one to predict these beneficial results. The lack of serious difficulties with these massive doses is surprising.


Part of the unexpected benefit at the high dose levels is frequently a feeling of well-being. This feeling of well-being, especially with the more toxic conditions, is despite the gas and diarrhea sometimes produced. If the malaise from the basic disease is great (e.g. mononucleosis, acute hepatitis, viral pneumonia, etc.), the obvious benefit from ascorbic acid is usually so great that the patient usually cares little about the minor gastrointestinal disturbances. Lowering dose levels too soon before bowel tolerance decreases, results in the return of the malaise and other acute symptoms of the disease. The_clinical_sensation_experienced_with_the_massive doses_of_ascorbate_is_one_of_"detox- ification"_as_a_threshold_is_reached. By raising and lowering the doses, the symptoms of "toxicity" can be readily turned off and on rapidly by some skilled patients.

I cannot emphasize enough that in "selected" patients (selected only by excellent tolerance to ascorbic acid, good understanding of the principles of determining the flexible bowel tolerance doses, and the willingness to follow directions in fine detail), this effect is invariable, dramatic, and unmistakable. The patient most likely to experience this effect is the psychologically stable, not suggestible, practical, not liking to be sick patient, with a "cast iron stomach." Children and teenagers, much as they may hate the taste of ascorbic acid in water, make particularly good patients once they experience the ameliorating effects of these massive doses. Infants, upon receiving very large intramuscular or intravenous injections, frequently "detoxify" in minutes to the astonishment and marked relief of their parents.

These feelings of well-being experienced by tolerant patients from the ingestion of massive doses of ascorbic acid are definite clinical indications that no acidosis or other acute toxic metabolic effect is resulting. Massive intravenous doses of sodium ascorbate are even more impressive than oral ascorbic acid, because the beneficial effects are even more dramatic and gastrointestinal gas and diarrhea are not produced. Patients who ordinarily would be relatively incapacitated, can usually remain functional and sometimes even participate in athletics if frequent and massive ascorbate doses are maintained.

Patients must be encouraged to take these massive doses. Patients taking vitamin C on their own, seldom take doses high enough to discover this effect. I do not want to give the impression that this method is easy to use; the mechanics of taking these doses can be very difficult for many patients. Nevertheless, when properly instructed, the majority of patients are able to achieve these effects. If a patient is relatively intolerant to oral ascorbate only because of gastrointestinal complaints, and if his disease is one that usually responds to oral ascorbate in tolerant patients, and if the severity of the condition warrants the inconvenience and expense, then intravenous ascorbate is indicated.

Such effects of these large doses of ascorbate cannot be readily explained from its known vitamin functions. The spectrum of diseases affected by massive doses of ascorbate is a wonder in itself, but also gives some hint at the probable mechanisms involved. The sudden detoxifying effect experienced clinically only at the very high threshold doses, suggests that ascorbate is participating in chemical reactions where a critical concentration of ascorbate is necessary, or where a certain ratio between ascorbate and certain other reactants must be achieved. The concept that free radicals and other highly reactive oxidants are a frequent factor in pathologic processes (7,8) and that ascorbate is an antioxidant free radical scavenger, could explain much of this.


Chemical reactions involving free radicals and highly reactive oxidants are necessary in the normal metabolism of cells. Metabolic processes utilizing oxygen (aerobic metabolism) which release energy are important examples. Ordinarily, these reactions occur in conjunction with appropriate enzymes or in the proper places within the cells. While it has been documented that potentially harmful reactants leak from their normal cellular confines and are potentially toxic (9), these rates of leakage are usually low enough for the natural antioxidant, free radical scavenging mechanisms to handle. One of the causes of natural aging may be that some (albeit small) portion of stray free radicals inevitably escape quenching (10). While the human body does contain many free radical scavenging mechanisms for the purpose of mopping up free radicals, I hypothesize that in_pathologic processes_these_rate-limited,_mechanisms_are_acutely_inadequate_t o_neutralize the_volume_of_free_radicals_produced. A threshold is reached where these additional free radicals produced, initiate an inflammatory cascade, can cause immune suppression, and can result in degenerative diseases.


In general free radical scavenging occurs through complex metabolic pathways involving many steps which are rate-limited. Deficiencies of nutrients, vitamins and minerals, which make up the enzymes and coenzymes of these systems can slow down or halt certain pathways.

It is apposite to describe one of these rate-limited, free radical scavenging mechanisms, to give the impression of its complexity and why it is rate-limited. The example chosen involves the glutathione pathway which is possibly one of the most important pathways.

When, for example, a superoxide radical must be destroyed, superoxide dismutase can catalyze its conversion to O2 and H2O2 (11). Ascorbate, nonenzamatically, also converts superoxide to H202 but is oxidized in the process to the ascorbate free radical and dehydroascorbate. The ascorbate free radical and the dehydroascorbate are reduced back to ascorbate either by NADH (catalyzed by semidehydroascorbate reductase and forming NAD) or reduced glutathione (GSH) (catalyzed by dehydroascorbate reductase and forming oxidized glutathione (GSSG)) (12). Some of the peroxide can be converted to oxygen and water by catalase but most will be destroyed by a glutathione-requiring enzyme system. GSH (catalyzed by glutathione peroxidase) reduces the peroxide to water but in the process is oxidized to GSSG. The resulting GSSG is reduced by NAD(P)H (catalyzed by glutathione reductase). The resulting NAD is reduced back to NADH by way of the Krebs cycle or resulting NADP is reduced back to NADPH by the hexose monophosphate (HMP) pathway. It is thought that commonly the rate-limiting step in the last series of reactions is that catalyzed by glutathione peroxidase and its cofactor selenium, but other substances which could limit all this are the vitamin E, vitamin C, vitamin B2, vitamin B3, cysteine, etc. Note: the ascorbate used in this example is as in the vitamin C sense; the small amount available is oxidized to dehydroascorbate and then must be reduced back to ascorbate by the pathway described, to be reused as ascorbate. One can easily see how this mechanism and similar mechanisms could be overwhelmed by a toxic pathogen liberating free radicals or by an inflammatory cascade regardless of its cause.


I further hypothesize that the pathogens of most acute infectious diseases depend upon free radical toxicity to defend themselves against immediate destruction by the immune system. If a pathogen produces free radicals at a rate sufficient to exceed the rate at which the host can produce free radical scavengers to protect the immune system, the pathogen will be free to invade and multiply. The more toxic pathogens produce more free radical toxins than just necessary to suppress the immune system. The spill over of free radicals reaches a threshold where an inflammatory cascade in the tissues affected, is initiated.

Neutrophils liberate free radicals and highly reactive oxidants both intracellularly and extracellularly in their attempt to destroy pathogens, in the process termed the respiratory burst (13-18). The respiratory burst consumes NADPH which must be continually restored if the respiratory burst is to be maintained. Restoration of NADPH supplies is accomplished by way of the HMP pathway, by various rate-limited enzymatic mechanisms.

I suggest that if rate-limited enzymatic processes or the limited availability of the antioxidant free radical scavenging mechanisms of the leukocytes, superoxide dismutase (18), catalase (20), glutathione peroxidase, and glutathione (21-23), fall short of being able to contain and direct free radicals and reactive oxidants toward the pathogen, that failure causes the free radicals to backfire, damage the host itself, and initiate an inflammatory cascade.

If a critical tissue concentration of free radical scavenger could protect the immune system from the free radicals produced by the pathogen, and would assist the leukocytes in modulating their own free radical generation, the immune system might be expected to prevail and destroy the pathogen rapidly by direct phagocytosis. If such a scavenger were found to be effective in large numbers of infectious diseases, it could imply that there was a common mechanism of free radical suppression of the immune system operative in all these diseases. Until such a free radical scavenger were recognized to exist, the commonality of such a mechanism to all these diseases might be overlooked. I hypothesize that ascorbate is, in fact, such a free radical scavenger when used in the doses being discussed. Its effectiveness in a wide spectrum of infectious diseases is evidence of the common mechanism many pathogens have of sup- pressing the immune system.

By neutralizing virtually all unwanted free radicals and toxic oxidants, massive doses of ascorbate can be made to protect the immune system to such a degree that early in acute viral diseases, the immune system can usually destroy the pathogen within hours. When used later in the course of an acute viral disease where the pathogen has established itself intracellularly in significant numbers of cells, massive doses of ascorbate can protect the immune system, suppress most symptoms, and prevent secondary complications until the immune system destroys the pathogen by secondary means such as with antibodies.

I have found that massive doses of ascorbate work synergistically with appropriate antibiotics when used against acute bacterial diseases, and broaden the spectrum of the antibiotics considerably. I have not been able to explore thoroughly the extent to which ascorbate can be used alone in bacterial diseases, but I have had some serendipitous clinical evidence that certain bacteria do very poorly in the face of massive doses of ascorbate even where antibiotics were not used.

Conditions involving indolent bacterial infections such as chronic bronchitis, sinusitis, otitis media, tonsillitis, osteomyelitis, nonspecific urethritis, etc., are frequently cured by massive doses of ascorbate. I_hypothesize_that_probably_induced_localized_scurvy_plays_a_deci sive_part_in a_pathologic_equilibrium_set_up_between_the_chronically_infected_ tissue_and_the pathogen. When the induced scurvy is eliminated by driving tissue levels of ascorbate up above a certain threshold, the immune system usually rapidly eliminates the infection and the affected areas heal.

Where allergies in combination with infections play a major role, massive doses of ascorbate are helpful but continuing maintenance doses will be required. In this situation, continuing blockade of the allergically-induced inflammatory cascade must be maintained.

With recurrent herpes virus infections, very high maintenance doses of ascorbate seem to prevent some attacks, and bowel tolerance doses will shorten and reduce the severity of attacks. A topically applied ascorbate paste (ascorbic acid or sodium ascorbate and water) (24) appears to be particularly effective on herpes simplex. In chronic hepatitis, ascorbate may not cure the condition; nevertheless, massive doses of ascorbate will usually ameliorate the condition; and I have evidence that shedding of the virus may stop. I have not determined whether the patient will resume shedding of the virus if large doses of ascorbate are discontinued. In conditions where a virus has become well established intracellularly, there are some limitations on the ability of ascorbate to assist the immune system.


More recently, I have found ascorbate useful in the management of the acquired immune deficiency syndrome (AIDS). The AIDS patient who has already suffered a marked suppression of helper T-cells, presents a clinical problem of management similar to a bubble baby. If, in addition to the other measures described in my previous reports (24,25), the patient takes bowel tolerance doses of ascorbic acid orally almost every hour (intra- venously in emergencies), he may remain clinically well despite the continuing severe suppression of the helper T-cells. All this must be started before multiple infections riddle the patient's body with excessive sources of free radicals. There have been suggestive anecdotal cases which indicate that in the prodromal period, before the destruction of the helper T-cells, there might be avoidance of the development of the AID syndrome by this program. Confirmation of this possibility awaits long- term laboratory follow-up. There is evidence that a retroviral infection in cats, the feline leukemia virus, can be cured in the prodromal stage with large oral doses of ascorbate used in combination with other nutrients (26).


It is my hypothesis that what makes ascorbate truly unique is that very large amounts can act as a nonrate-limited antioxidant free radical scavenger.

Clinically, ascorbate is virtually nontoxic (27,28,4). But as ascorbate acts as an antioxidant free radical scavenger in the body, it is oxidized to dehydroascorbate. There are animal experiments that indicate that dehydroascorbate is toxic (29-31). However, dehydroascorbate is not administered directly to humans as it was in the animal experiments. Whatever dehydro- ascorbate comes to exist in the human body, comes by way of the oxidation of ascorbate, as the ascorbate is utilized to reduce free radicals or other reactive oxidizing substances. The potential of the dehydroascorbate to do damage should be less than the harmful potential of the substances it reduces to become dehydroascorbate (the oxidizing redox potential has been diminished). Therefore a patient should not be expected to be more toxic from the dehydroascorbate formed than he was from the original disease unless there is some peculiar specific sensitiv- ity to dehydroascorbate (see discussion of G-6-PD deficiencies below).

Used in the doses I suggest, there is an even more important mechanism which prevents toxicity from dehydroascor- bate. I take advantage of a combination of the facts that even in enormous doses, ascorbate is not clinically toxic, and that dehydroascorbate is only toxic when there is a low AA/DHA ratio.


Several (32-36) have hypothesized and reviewed many of the biochemical advantages of large doses of ascorbate. Of particular interest are Lewin's calculations and hypotheses (34) that high tissue concentrations of ascorbate to dehydroascorbate can directly reduce various substances (e.g. the disulfides). I doubt that tissue levels of ascorbate achieved with doses much below bowel tolerance are sufficient to significantly accomplish these reductions under pathological circumstances. Clinically however, something very dramatic happens as bowel tolerance is approached. I hypothesize that as a certain threshold ratio of ascorbate to dehydroascorbate is reached, certain direct reductions of substances such as oxidized glutathione and adreno- chrome by ascorbate begin. When a patient is sick or experiencing much stress, the amounts of these substances which can potentially and beneficially be reduced, increases greatly. If ascorbate is not available to reduce these substances, those that escape reduction to nontoxic derivatives by the rate-limited, antioxidant free radical scavenging mechanisms, damage the patient and cause symptoms. Under these circumstances, when made available, large amounts of ascorbate are utilized for these direct reducing purposes. These ascorbate reductions are not rate-limited, and therefore quench the harmful oxidants and free radicals almost instantly.

When the potential need for ascorbate for these purposes is satisfied, the blood level of ascorbate rises and retards the absorption of ascorbate from the gut. Soon, sufficient amounts of ascorbate reach the rectum to produce diarrhea.

Based on clinical evidence, I hypothesize that ascorbate can maintain this reducing redox potential under very adverse circumstances, but that the doses necessary to do this are enormous by any other standards. This antioxidant free radical scavenging effect of enormous doses of ascorbate seems not particularly contingent upon other nutrients. However, vitamin functions of lower doses of vitamin C are frequently potentiated by and work in conjunction with vitamin A, zinc, selenium, bioflavonoids, and other nutrients which play roles in various defense mechanisms.

Chayen has discussed the significance of redox couples and has emphasized that whether a reaction will proceed left to right, or in reverse, depends upon the ratio of the oxidized to the reduced members of a redox couple. He suggests designing "redox drugs" as a possible way of treating imbalances of oxidation-reduction potentials of critical intracellular systems (37).


I would anticipate that if it were possible to eliminate the vast majority of stray free radicals and highly reactant oxidative substances, the usual inflammatory cascade would not occur following injury or surgery. Pain, complications, and recovery times would be reduced. In conditions resulting from combinations of mechanical derangements, nutritional deficien- cies, immune dysregulations, hemorrhage with release of free radical generating iron and copper atoms, and then secondary inflammatory cascades (e.g. degenerative disc disease, degenera- tive arthritis, rheumatoid arthritis, ankylosing spondylitis, blunt trauma of the spine, etc.), therapeutic effects could be expected proportional to what might result from blocking of the free radicals and the inflammatory cascade. Reversal of the mechanical and nonfree radical injury could not be expected, although certain healing mechanisms might be enhanced.

Toxic substances, whose mechanisms of action involve free radical generation, e.g. toxic poisons such as snake bites and spider bites, certain drugs, such as barbiturates, chemotherapeutic agents, narcotics, and powerful oxidizing pollutant chemicals, might be neutralized. Conditions triggered by allergic reactions and perpetuated by the inflammatory cascade might be expected to be partially alleviated. Psychological symptoms resulting from oxidative products such as adrenochrome and noradrenochrome (38), would be expected to be ameliorated to a degree.

Tumors invading the body or holding off the immune system by way of free radical toxicity might be expected to respond to varying degrees. As an increasing number of human cancers are recognized as probably being caused and possibly maintained by infectious organisms (e.g. Kaposi's lesions by the CMV (39), some adult T-cell lymphomas by the HTLV (40), certain cervical and vaginal cancers by the papilloma virus (41,42)), it should not be surprising if such tumors would respond in various degrees to ascorbate. Since any treatment of cancers by a physician with nutritional substances is incredibly a felony in California in 1984, it may be practical to recognize early that a tumor caused by a virus should no longer be considered a cancer (e.g. Kaposi's lesions).

If, to these diseases, we add conditions benefitted which could be caused or aggravated by actual dietary deficiency of vitamin C, or from an acute induced deficiency of vitamin C, there is a very close approximation to the clinical spectrum of disease conditions which in the experience of those actually using such doses (4,26-28,32,33,43,44), appear to be beneficially affected. In a rough way, these conditions are ameliorated to the degree that one might anticipate if this ideal mechanism of being able to quench all stray free radicals and highly reactant oxidative substances, were actually accomplished.


There is fear that ascorbate given in large amounts to patients with G-6-PD deficiencies would cause hemolysis (45,46). In a case where a black man with G-6-PD deficiency who sustained a burn of one hand was given 80 grams of ascorbic acid intravenously on each of 2 consecutive days, the patient subsequently suffered hemolysis, renal failure, a stroke, coma, and then death (46). There are available for intravenous use, solutions of actual ascorbic acid rather than sodium ascorbate; ascorbic acid, in my opinion, should never be used in any large amount intravenously. It must be buffered to reduce the acidity. There are also preparations labelled vitamin C that contain preservatives which also should never be used. It was not clear from the article what preparations had been used.

The sequence of reactions whereby certain drugs cause hemolysis with G-6-PD deficiency is poorly understood. It appears that G-6-PD deficient cells lack a mechanism to regenerate reduced glutathione (GSH) from oxidized glutathione (GSSG) and that this lack may result in several biochemical alterations, the final result being hemolysis of the red cells. The maintenance of glutathione in the reduced state (GSH) is probably the most important function of the HMP pathway. It may be that the hemolysis caused by certain drugs is initiated by the drug forming either free radicals or hydrogen peroxide. When peroxides are reduced back to water, GSH is oxidized to GSSG, a reaction catalyzed by glutathione peroxidase. Ordinarily the GSSG is reduced back to GSH by NADPH, a reduction catalyzed by glutathione reductase. The resulting oxidized NADP is reduced back to NADPH in the first step of the HMP pathway, as glucose-6- phosphate is oxidized to 6-phosphogluconolactone. This critical reaction is catalyzed by G-6-PD. G-6-PD deficient cells may be expected to accumulate peroxides which could then oxidize other red cell components (see review in 47).

As discussed previously, if the AA/DHA redox potential is kept reducing enough by high enough concentrations of ascorbate, it should directly reduce the GSSG to GSH. I hypothesize that this mechanism should compensate for the lack of G-6-PD; but I would offer some words of caution. I have no clinical experience with this condition. It is apparent, however, that in the case reported that the redox potential was not kept consistently on the reducing side throughout the course of treatment and that there might have been variables not appreciated at the time which were very important.

With the increasing millions of persons taking large doses of vitamin C, it is inevitable that individuals with G-6-PD deficiencies will take these doses. Serendipitous data should be collected. I would appreciate receiving any well documented case histories.

It is important to understand that G-6-PD deficiencies have a wide range of clinical severities. Severe deficiencies are rare and found in Mediterranean and Asian groups. Blacks have a milder form but with higher frequency of occurrence. There is substantial decrease in the activity of G-6-PD with aging. The possibilities exist that in certain individuals with various degrees and forms of G-6-PD deficiencies that: 1) vitamin C has no deleterious effect; 2) vitamin C has a peculiar effect on that person such that any significant amount causes hemolysis; 3) vitamin C in low or moderate amounts will produce hemolysis, while massive amounts maintaining a continuing reduced redox potential will not cause hemolysis and will prevent the hemolysis from other causes. (This last possibility will not be determined unless those administering the ascorbate are very aggressive and do not let up the doses until whatever was the cause for which the ascorbate was given in the first place, is completely passed.)

As the immense value of ascorbate in the doses I am describing becomes entirely apparent in normal people, the theoretical possibility of preventing hemolysis in G-6-PD deficient persons subjected to pathologic oxidative stress, which would result in massive hemolysis of blood cells anyway, may be recognized. Meanwhile, I_advise_that_large_doses_of_ascorbate not_be_given_G-6-PD_deficient_patients. I suggest the possibility that all this may apply to G-6-PD deficiency only to stimulate the collection of data and to suggest research on the subject.

Calabrese has suggested that megadoses of ascorbic acid might pose a hemolytic risk to persons with sickle cell trait and sickle cell anemia because their erythrocytes possess more copper than normal persons and that ascorbic acid markedly enhances copper induced hemolysis (48). Again I suggest that it is possible that if ascorbate is given in large enough amounts during a sickle cell crisis, it may keep the redox potential of the various problem systems reducing. Vitamin E might futher facilitate beneficial effects (49).


One might remain unnecessarily cautious in the use of ascorbate because of my qualification about "tolerant" patients. Any real problems have been rare. I cannot recall any patient who has been damaged by large doses of ascorbate (other than the topical effect of the acid on tooth enamel). Some preexisting gastrointestinal tract difficulties, such as peptic ulcer or colitis, may have been aggravated by topical effects, but advice on these is difficult to give because more frequently the same conditions may be benefitted. All these topical difficulties are circumvented by using intravenous ascorbate.

A high percentage of persons with food and/or chemical sensitivities may have nuisance difficulties with vitamin C. However, attempts to have these sensitive patients take ascorbate should be made because great benefits can often be obtained, particularly from calcium, magnesium, and potassium ascorbate, in many of these patients. Frequently, after the administration of selenium, ascorbate is better tolerated by chemically allergic patients. Levine has suggested that chemically allergic patients frequently benefit from selenium because selenium augments the glutathione peroxidase activity (8). I have had some clinical evidence that certain chemically allergic patients who force through nuisance problems of low doses of ascorbate, can derive benefits from consistently taken large doses. It may be that chemically allergic persons accumulate dehydroascorbate more readily than others because of a deficiency of glutathione per- oxidase. I had one chemically allergic patient who responded well to intravenous ascorbate until an hour after it was discon- tinued. She then developed a severe headache that lasted several hours. In retrospect, it seems possible that the intravenous ascorbate was able to maintain a reducing redox potential, which then returned to the oxidizing side after the intravenous ascorbate was discontinued.

True allergic reactions seem always traceable to substances from which the ascorbate is made, or chemicals used in its manufacture, and not to the ascorbate itself.


Oxalate kidney stones have been suggested as a theoretical problem, in that oxalate is one of the breakdown products of ascorbate (50). In my experience clinically, ascorbate in these doses not only does not cause kidney stones but seems to prevent stones in patients who have had them previously. The slight increase in the acidity of the urine from ascorbate (51,52), and the slight diuresis (53) solubilizes calcium salts. I think that high concentrations of ascorbate, by being bacteriostatic in the urine, should prevent many of the niduses of infection around which oxalate stones frequently form. The increased ascorbate concentration complexes Ca++ and thereby decreases the amount of Ca++ available to complex with oxalate (34). Here again is the paradoxical situation where with small doses of vitamin C, it is possible that where most of the nutrient is oxidized to dehydro- ascorbate and then some to oxalic acid, it is theoretically possible that there could be a slight increase in tendency to form stones. However, I find it difficult to believe that if this were the case, that this tendency would not have been noticed with the millions taking small doses of vitamin C. I hypothesize that by using the bowel tolerance method of determining the dosages of ascorbate to be taken, that no matter how much dehydroascorbate is formed and hence oxalic acid, the spill of ascorbate in the urine will be kept very high and should prevent oxalate stones.


I suggest that the enormous draw on ascorbate for free radical scavenging purposes, can exhaust the vitamin C available for known housekeeping functions of the vitamin. I term this condition acute_induced_scurvy. This deficiency starts in the tissues directly involved in the disease; then blood levels of vitamin C drop (anascorbemia); and then tissues distant from the primary focus of the disease become involved. Secondary complications occur which can be averted by fully satisfying the increased need for ascorbate (4).

A very important part of these very large doses of ascorbate being able to assist the immune system against pathogens is likely that serum levels and leukocyte levels of ascorbate are raised enough to drive ascorbate into the depths of infected tissues. The amount of ascorbate needed to satisfy the enormous potential utilization of ascorbate as an antioxidant free radical scavenger in the depths of the diseased tissues is provided. The shut down of vitamin C dependent housekeeping functions of affected cells and the shut down of vitamin C dependent immune system functions are prevented.


I think that many crib deaths are caused by this acute induced scurvy even before it is evident that the infant is sick with some infectious disease. Kalokerinos (28) has demonstrated the value of vitamin C in preventing crib deaths. I have seen enormous increases in bowel tolerance to ascorbate in adults several hours before there was any outward sign of their getting sick. It is easy to imagine certain vital centers in an infant failing when suddenly deprived of vitamin C by the ascorbate being used up for acute free radical scavenging purposes. For_many_reasons, it is unfortunate that the free radical scavenger ascorbate is the same substance as vitamin C.Infants tolerate ascorbate well. In addition to substantial maintenance doses of vitamin C, even infants should be given large doses of ascorbate when ill. Amounts should be given sufficient to relieve fever, irritability, and other outward signs of toxicity (4).


While it is not denied that there could be very rare serious complications associated with the use of massive doses of ascorbate, fear of this possibility should not retard use of the substance in patients with normal metabolism. In my experience, the margin of safety (therapeutic index or selectivity) for massive doses of ascorbate as related to significant complica- tions is greater than aspirin, antihistamines, antibiotics, all pain medications, muscle relaxants, tranquilizers, sedatives, diuretics, etc. Not only is the margin of safety of ascorbate extremely favorable but when used with most of these drugs, the combination frequently acts synergistically and has a margin of safety greater than with the drug alone. While ascorbate may block the effects of some sedatives and narcotics, massive doses of ascorbate frequently alleviate the need for those substances.

Clinically, ascorbate in the very large doses described is very effective and safe as part of the treatment of a wide variety of conditions, especially infectious diseases. It is my hypothesis that this clinical effectiveness when a critical threshold is reached, as indicated by bowel intolerance to ascorbic acid in the form of diarrhea, occurs both because massive doses of ascorbate can act as a nonrate-limited, antioxidant free radical scavenger and because acute induced scurvy is avoided. When high enough tissue levels are reached in tissues directly affected by the disease processes, the redox potential of the AA/DHA system in those tissues is kept reducing; substances such as oxidized glutathione are directly reduced; and stray free radicals are rapidly quenched.

This effect of ascorbate is rate-limited only by the lack of courage of those administering ascorbate or the tolerance of the patient taking it. I hope to increase that courage by pointing out the observed lack of toxicity clinically and the theoretical reasons for that lack of toxicity.

This effect, when understood, opens up a wide range of opportunities to understand certain pathological processes. It is especially important in the case of infectious diseases because of the probable common mechanism of free radical toxicity that many pathogens have of suppressing the immune system. The increasing bowel tolerance to ascorbic acid can be used as a fairly accurate measure of the "toxicity" and activity of certain disease processes.

In toxic conditions, the use of ascorbate by the body for these scavenging purposes, results in such a localized and systemic deficiency of vitamin C that there is not enough of the nutrient remaining for vitamin C dependent housekeeping functions. I call this condition acute_induced scurvy. This condition can be induced by any stress and is responsible for a high percentage of the secondary complications of many diseases. The magnitude of this scavenging drain on ascorbate is enormous as revealed by the increasing bowel tolerance to ascorbic acid somewhat proportional to the toxicity of the disease process. Only the doses discussed can fully satisfy this need.

I think that most crib deaths are due to acute induced scurvy.

I have hypothesized here that massive doses of ascorbate may paradoxically be of benefit in G-6-PD deficiency, but have urged caution until more data is obtained. Ascorbate, when used with care, can be of great benefit in chemically allergic patients.

Rinse ascorbic acid and carbonated ascorbates off the teeth as prolonged exposure may cause damage to the enamel.


Partly supported by the Burton Goldberg Foundation. The author appreciates the comments of Stephen A. Levine and Parris M. Kidd.


Dr. Cathcart 

1.  Cathcart RF. Clinical trial of vitamin C. Letter to the
Editor, Medical     Tribune, June 25, 1975. 
2.  Cathcart RF. The method of determining proper doses of
vitamin C for     the treatment of diseases by titrating to bowel
tolerance. The Australian     Nurses Journal 9(4):9-13, Mar 1980.

3.  Cathcart RF. The method of determining proper doses of
vitamin C for  the treatment of disease by titrating to bowel
tolerance. J Orthomolecular Psychiatry 10:125-132, 1981.

4.  Cathcart RF. Vitamin C: titrating to bowel tolerance,
anascorbemia, and acute induced scurvy. 
Medical Hypotheses 7:1359-1376, 1981.

5.  Cathcart RF. C-vitaminbehandling till tarmintolerans vid
infektioner     och allergi. Biologisk Medicin 3:6-8, 1983. 

6.  Cathcart RF. Vitamin C: titrating to bowel tolerance,
anascorbemia, and acute induced scurvy.
Let's Live (Japan) 16:9, Nov 1983.

7.  Demopoulos HB. The basis of free radical pathology. Fed Proc
32:1859-    1861, 1973.

8.  Levine SA, Reinhardt JH.  Biochemical-pathology initiated by
free     radicals, oxidant chemicals, and therapeutic drugs in
the etiology     of chemical hypersensitivity disease.
J Orthomolecular Psychiatry     12(3):166-183, 1983.

9.  Levine SA, Kidd PM. Free Radical Pathology and Antioxidant
    tion.  Biocurrents Research, 944 Lake St., San Francisco, CA
94118,     In press, 1984.

10. Harman D.  The aging process. Proc Natl Acad Sci USA
78:7124-7128,     1981.

11. Fridovich I. Superoxide dismutase. Adv Enzymol, 41:35-97,

12. Liebovitz BE, Siegel BV. Aspects of free radical reactions in
biological     systems: aging. J. Gerontol 35:45-56, 1980.

13. Baldridge CW, Gerard RW. The extra respiration of phago-
cytosis.  Am J Phy    siol 103:235-236, 1933.

14. Sbarra AJ, Karnovsky ML. The biochemical basis of phagocyto-
sis. I. Metabo    lic changes during the ingestion of particles
by polymorphonuclear     leukocytes.  J Biol Chem 234:1355-1362,
15. Iyer GYN, Islam MF, Quastel JH.  Biochemical aspects of
phagocytosis.      Nature 192:535-541, 1961.

16. Babior BM, Curnutte JT, McMurrich BJ. The particulate
superoxide-forming     system from human neutrophiles. J Clin
Invest 58(4):989-996, 1976.

17. Babior BM. The role of active oxygen microbial killing by
phagocytes. In Autor, A.P. (ed). Pathology of Oxygen. 
Academic Press, New York,     45-58, 1982.

18. Babior BM, Crowley CA. Chronic Granulomatous Disease and
other disorders     of oxidative killing by phagocytes. p
1956-1985 in Stanbury, J.B. (ed)     et al. The Metabolic Basis
of Inherited Disease, 5th Ed., McGraw-Hill     Book Company, New
York, 1983.

19. Salin ML, McCord JM. Superoxide dismutase in
polymorphonuclear leuko    cytes. J Clin Invest 54:1005-1009,

20. Roos D, Weening RS, Wyss SR, Aebi HE. Protection of human
neutrophils     by endogenous catalase. Studies with cells from
catalase-deficient     individuals. J Clin Invest 65:1515-1522,

21. Reed PW. Glutathione and the hexose monophosphate shunt in
phagocytizing     and hydrogen peroxide-treated rat leukocytes. J
Biol Chem 244:2459-    2464, 1969.

22. Strauss RR, Paul BB, Jacobs AA, Sbarra AJ. The role of the
phagocyte     in host-parasite interactions. XIX. Leukocytic
glutathione reductase     and its involvement in
phagocytosis. Arch Biochem Biophys 135:265-271,     1969.

23. Vogt MT, Thomas C, Vassollo CL, Basford RE, Gee JBL. Gluta-
thione-dependent     peroxidative metabolism in the alveolar
macrophage. J Clin Invest     50:401-410, 1971.

24. Cathcart RF. Vitamin C in the treatment of acquired immune
deficiency syndrome (AIDS).
Medical Hypotheses 14(4):423-433, Aug 1984.

25. Cathcart RF. Vitamin C function in AIDS. Current Opinion,
Medical Tribune, July 13, 1983.
26. Belfield WO. Zucker M. The Healthy Cat Book.  McGraw Hill,

27. Klenner FR. Observations on the dose and administration of
ascorbic     acid when employed beyond the range of a vitamin in
human pathology.     J App Nutr 23:61-88, 1971.  

28. Kalokerinos A.  Every Second Child.  Keats Publishing, Inc.,
New Canaan,     1981 
29. Patterson JW. The diabetogenic effect of dehydroascorbic and
    isoascorbic acids. J Biol Chem, 183:81-88, 1950.

30. MacDonald MK, Bhattacharya SK. Histological changes in rats
rendered     hyperglycaemic by injection of dehydroascorbic acid.
Quart J Exp Physiol     41(2):153-161, 1956.

31. Massina A, Brucchieri A, Gasso G. Diabete sperimentale da
acido deidro    ascorbico. Botl Soc Ital Biol Sper 44(14): 1138-
1141, 1968

32. Stone I. The Healing Factor: Vitamin C Against Disease.
Grosset and     Dunlap, New York, 1972. 
33. Pauling L. Vitamin C and the Common Cold. W.H. Freeman and
Company,     San Francisco, 1970. 
34. Lewin S. Vitamin C: Its Molecular Biology and Medical
Potential. Academic     Press, 1976. 

35. Cheraskin E, Ringsdorf WM, Sisley EL. The Vitamin C
Connection. Harper     & Row, New York, 1983.

36. Basu TK Schorah CJ. Vitamin C in Health and Disease. The AVI
Publishing     Company, Inc., 1982. 

37. Chayen J. Editorial: Concerning the possibility of redox
drugs.  Agents     and Actions 12(4):531-535, 1982.

38. Hoffer A. Oxidation-reduction and the brain. 
J Orthomolecular Psy    chaitry 12:292-301, 1983.  

39. Giraldo G, et al. Kaposi's sarcoma and its relationship to
Int J Cancer 26:23-29, 1980.

40. Poiesz BF, et al. Detection and isolation of type C
retrovirus particles     from fresh and cultured lymphocytes 
of a patient with cutaneous T-cell lymphoma.
Proc Natl Acad Sci 77:7415-7419, 1980.

41. Green M, et al. Isolation of a human papillomavirus from a
patient     with epidemodysplasia verruciformis: Presence of
related viral DNA genomes in human urogenital tumors. 
Proc Natl Acad Sci 79:4437-4441, 1982.

42. zur Hausen H.  Human genital cancer: Synergism between the
two virus infections or synergism between a virus infection
and initiating  events?  Lancet 1:1370-1372, 1982.

43. Cameron E, Pauling L.  Cancer and Vitamin C. The Linus
Pauling Institute for Science and Medicine, Menlo Park, 1979.

44. Hoffer A, Osmond H, Smythies J.  Schizophrenia: A new
approach II, Results of a years research.
J Ment Sc 100:29-45, 1954.

45. Mengel CE, Green HL, Ascorbic acid effects on
erythrocytes. Ann Intern     Med 84:490, 1976.

46. Campbell GD, Steinberg MH, Bower JD. Ascorbic acid-induced
hemolysis in G-6-PD deficiency. Ann Intern Med 82:810, 1975.

47. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. In
Stanbury  JB et al (Eds.) The Metabolic Basis of Inherited
Disease, McGraw Hill     Book Company, New York, 1983.

48. Calabrese EJ. Does consumption of mega-doses of ascorbic acid
pose a hemolytic risk to persons with sickle cell trait and
sickle cell anemia. Med Hypostheses 9(6)647-649, 1982.

49. Natto CL, Machlin LJ, Brin M. A decrease in irreversibility
sickled erythrocytes in sickle cell anemia patients given
vitamin E. Am JClin Nutr 33:968-971, 1980.

50. Burness LA. Safety considerations with high ascorbic acid
dosage.  In Second Conference on Vitamin C, King CG, Burns JJ
(Eds) Ann NY Acad Sci 258:523-527, 1975.

51. McDonald DF, Murphy GP. Bacteriostatic and acidifying effects
of methionine, hydrolysed casein and ascorbic acid on the
urine, New England J Med 261:803-805, 1959.

52. Murphy FJ, Zelman S. Ascorbic acid as a urinary acidifying
agent: I. Comparison with the ketogenic effect of fasting. 
J Urology 94:297-299, 1965.

53. Abbasy MA. The diuretic effect of vitamin C. 
Biochem J 31:339-342, 1937.

Content (C) 1995 and prior years,  Robert F. Cathcart., M.D.

Robert F. Cathcart,M.D.


Related Resource Lists:

Aids * Allergy * Candida / Yeast * Chron.Fatigue * Immune
Enviro Illness / Multi-Chem Sensitivity * Health * Med *

For your web space and web photography needs, contact webmaster@mall-net.com